Glutathione
US$ 25.25
foxo4-dri cancer Peptide Dosing Guide: Senolytic Peptide Protocol (June 2026) Molecular modelling of the FOXO4-TP53
Description
Results announced in December 2025 confirmed the Phase 2 findings at a longer timepoint (Lilly Press Release, Dec 2025): The 28.7% weight loss at 68 weeks exceeds both semaglutide (~15% in STEP trials) and tirzepatide (~22.5% in SURMOUNT trials) at similar timepoints
The recommendation to cycle it: Did not come from research Did not come from pharmacology Did not come from clinical trials It came from gym culture
That definitely is an added benefit, and in the meantime im working on my on my other issues
Convenience Winner: Timeline Mitopure Convenience can be a somewhat tricky criterion
